For healthy older adults, the risks of taking daily aspirin (serious bleeding) outweigh any potential benefits (no reduction in death, dementia, or disability), so it should not be used to prevent aging-related health problems.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all RCTs would definitively determine whether the net effect of low-dose aspirin in healthy elderly adults is harmful, beneficial, or neutral by combining data on disability-free survival and major hemorrhage across trials.
A systematic review and meta-analysis of all randomized controlled trials comparing daily low-dose aspirin (75–100 mg) to placebo in adults aged 65 or older without cardiovascular disease, with disability-free survival and major hemorrhage as co-primary outcomes, using individual participant data to calculate net benefit/harm ratios and risk-benefit thresholds across subgroups.
A new RCT with a composite primary outcome of net clinical benefit (disability-free survival minus major hemorrhage) could definitively determine whether aspirin’s harms outweigh its benefits in this population.
A double-blind, placebo-controlled RCT of 25,000 healthy adults aged 70–80, randomized to 100 mg aspirin or placebo daily, with a pre-specified primary outcome of net clinical benefit: a composite of disability-free survival minus major hemorrhage, analyzed using competing risks methodology and adjusted for age, sex, and frailty, over 7 years.
A prospective cohort could estimate the real-world net clinical impact of aspirin use in elderly populations by tracking both disability-free survival and hemorrhage events over time.
A prospective cohort study following 50,000 adults aged 70+ in electronic health record databases for 10 years, tracking aspirin use, disability-free survival (via hospitalizations, cognitive assessments, and mortality), and major hemorrhage events, with multivariable modeling to estimate net benefit/harm ratios adjusted for comorbidities and medication use.
A case-control study could assess whether aspirin use is associated with a net negative clinical outcome (e.g., death or disability plus hemorrhage) compared to no aspirin use.
A case-control study comparing 2,000 elderly patients with a net negative outcome (death, disability, or major hemorrhage) to 2,000 matched controls without such outcomes, using pharmacy records and clinical data to assess prior aspirin use, adjusting for age, sex, and vascular risk factors.
A cross-sectional survey could estimate the prevalence of aspirin use and concurrent disability or hemorrhage in elderly populations at a single point in time.
A cross-sectional survey of 15,000 adults aged 70+ in primary care clinics, assessing current aspirin use and current presence of disability (Katz ADL) or history of major hemorrhage, with adjustment for age, sex, and comorbidities.